FASENRA SCEI for Long-term Use

AstraZeneca

Status: Active, not recruiting

Conditions: Asthma

Study type: Observational

Funder types: Industry

Identifiers

NCT03588546

D3250C00057

Details and patient eligibility

About

The purpose of the investigation is to confirm the safety and efficacy under the post-marketing actual long-term use of FASENRA Subcutaneous Injection 30 mg Syringe.

Full description

The purpose of the investigation is to confirm the followings under the post-marketing actual long-term use of FASENRA Subcutaneous Injection 30 mg Syringe.

1. Detection of unexpected Adverse Drug Reactions
2. To grasp development of Adverse Drug Reactions
3. To grasp contributing factors possibly having an impact on the safety and efficacy
4. Development of key investigational safety specification (serious infection).

Enrollment: 653 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

-The evaluable patients treated with Fasenra for the first time due to "Bronchial asthma (only the patients with intractable bronchial asthma which could not be controlled with the existing therapy).

Exclusion criteria

-No past history of hypersensitivity to the components of Fasenra.